Pharmacogenomic exposure amplification: a standard SSRI dose can feel like 3–4× in slow metabolizers
u/drwillpowers
r/DrWillPowers2026-06-07T22:45:26Z
Dr Will Powers’ own statements and theorizing
Mentions treatments or doses — not guidance
Summary (paraphrased)
Replying to a commenter flagging CYP2D6 slow-metabolizer variants surfacing in community-read PSSD genomes, Powers describes a genetic variant that amplifies SSRI exposure — a standard dose can feel like three to four times the dose — and notes the same gene directly synthesizes dopamine from tyrosine in the brain. He treats it as a risk variable for PSSD susceptibility, explicitly not "the answer."
Key points (paraphrased)
- Pharmacogenomic exposure amplification: a standard SSRI dose can feel like 3–4× in slow metabolizers.
- The same gene directly synthesizes dopamine from tyrosine — dual relevance to PSSD.
- Framed explicitly as a risk variable, not a causal answer.
- Community-sourced signal: CYP2D6 variants overrepresented in PSSD genome reads.
Why it’s in the corpus
The pharmacogenomic susceptibility angle for PSSD — dose-exposure amplification plus a dopamine-synthesis link. Documents a community-sourced variant signal and his discipline in labeling it a risk variable rather than an answer.
Context — the post Powers was replying toVerbatim third-party text, shown for context only — not Powers’ statement. Usernames removed.ShowHide
Powers' comment replies to [username removed], who flagged that CYP2D6 slow-metabolism variants appear overrepresented in PSSD genomes the community has been reading (against ~14% population prevalence), in the "Genes from your list (PSSD)" thread where the OP posted gene results after Zoloft-taper PSSD onset.
(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)
Some fields on this page come from the release’s Markdown edition, which carries text the JSON edition omits.
Related records
- Peer-reviewed paperPSSD Discord pick
CYP2D in the brain
Yoshihiko Funae, Wataru Kishimoto, Toshio Cho, Toshiro Niwa, Toyoko Hiroi · Drug Metabolism and Pharmacokinetics
This review surveys CYP2D isoforms in the brain: in rats CYP2D4 mRNA is most abundant in cerebellum, striatum, pons and medulla, while in humans only CYP2D6 is expressed, highest in cerebellum. It reports that CYP2D enzymes metabolize both xenobiotics…
CYP2D6DISC-0232003PFSPSSDPSSD Discord picks - Peer-reviewed paper
Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study
Farhana Islam, Leen Magarbeh, Samar S. M. Elsheikh, Stefan M. Kloiber, Caroline Wanderley Espinola, Venkat Bhat, Benicio Noronha Frey… · The Canadian Journal of Psychiatry
In 178 adults with major depressive disorder treated with escitalopram (weeks 0-8), nonresponders were augmented with aripiprazole while responders continued escitalopram alone (weeks 8-16), with sexual function and satisfaction tracked on the SexFX scale…
ABCB1CYP2C19CYP2D6MECH-0352023 (epub Oct 2023)PSSDSystems review · Oct 2026 - Peer-reviewed paperPSSD Discord pick
Potential role of CYP2D6 in the central nervous system
Cheng J, Zhen Y, Miksys S, Beyoğlu D, Krausz KW, Tyndale RF, Yu A, Idle JR, Gonzalez FJ · Xenobiotica
Mouse study using a transgenic human-CYP2D6 model, finding that human CYP2D6 is expressed not only in liver but also in brain, where it altered serotonin and metabolite levels plus broader brain metabolomic profiles, and shifted anxiety-related behavior. The…
CYP2D6DISC-0052013PSSDPSSD Discord picks